Literature DB >> 30521975

Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Yoshihiro Inamoto1, Igor Petriček2, Linda Burns3, Saurabh Chhabra4, Zachariah DeFilipp5, Peiman Hematti6, Alicia Rovó7, Raquel Schears8, Ami Shah9, Vaibhav Agrawal10, Aisha Ahmed11, Ibrahim Ahmed12, Asim Ali13, Mahmoud Aljurf14, Hassan Alkhateeb8, Amer Beitinjaneh15, Neel Bhatt16, Dave Buchbinder17, Michael Byrne18, Natalie Callander19, Kristina Fahnehjelm20, Nosha Farhadfar21, Robert Peter Gale22, Siddhartha Ganguly23, Shahrukh Hashmi14, Gerhard C Hildebrandt24, Erich Horn21, Ann Jakubowski25, Rammurti T Kamble26, Jason Law27, Catherine Lee28, Sunita Nathan29, Olaf Penack30, Ravi Pingali31, Pinki Prasad32, Drazen Pulanic33, Seth Rotz34, Aditya Shreenivas35, Amir Steinberg35, Khalid Tabbara36, André Tichelli37, Baldeep Wirk38, Jean Yared39, Grzegorz W Basak40, Minoo Battiwalla41, Rafael Duarte42, Bipin N Savani18, Mary E D Flowers43, Bronwen E Shaw16, Nuria Valdés-Sanz44.   

Abstract

Non-graft-versus-host disease (GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT) but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.
Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complication; Eye; Hematopoietic cell transplantation; Prevention; Review; Treatment

Mesh:

Year:  2018        PMID: 30521975      PMCID: PMC6511311          DOI: 10.1016/j.bbmt.2018.11.033

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  99 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

2.  Outcomes of cataract surgery in graft-versus-host disease.

Authors:  Rafael de Melo Franco; Michelle M Kron-Gray; Paola De la Parra-Colin; Yan He; David C Musch; Shahzad I Mian; Leslie Niziol; H Kaz Soong
Journal:  Cornea       Date:  2015-05       Impact factor: 2.651

3.  Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion.

Authors:  Yoav Y Pikkel; Adi Sharabi-Nov; Itzchak Beiran; Joseph Pikkel
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

4.  Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.

Authors:  David L Epstein; Peep V Algvere; Gunvor von Wendt; Stefan Seregard; Anders Kvanta
Journal:  Ophthalmology       Date:  2012-08-17       Impact factor: 12.079

5.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

6.  Visual outcome and cataract development after allogeneic stem-cell transplantation in children.

Authors:  Kristina Teär Fahnehjelm; Alba-Lucia Törnquist; Monica Olsson; Jacek Winiarski
Journal:  Acta Ophthalmol Scand       Date:  2007-08-28

7.  Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program.

Authors:  Martin Mynarek; Tina Ganzenmueller; Annika Mueller-Heine; Christopher Mielke; Andrea Gonnermann; Rita Beier; Martin Sauer; Britta Eiz-Vesper; Ute Kohstall; Karl-Walter Sykora; Albert Heim; Britta Maecker-Kolhoff
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-19       Impact factor: 5.742

8.  Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation.

Authors:  M C Benyunes; K M Sullivan; H J Deeg; M Mori; W Meyer; L Fisher; R Bensinger; M K Jack; J Hicks; R Witherspoon
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-06-15       Impact factor: 7.038

9.  Immunosuppressive Treatment Can Alter Visual Performance in the Royal College of Surgeons Rat.

Authors:  Ann E Cooper; Jang-Hyeon Cho; Steven Menges; Sahar Masood; Jun Xie; Jing Yang; Henry Klassen
Journal:  J Ocul Pharmacol Ther       Date:  2016-03-23       Impact factor: 2.671

10.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

View more
  1 in total

1.  Vision-specific and cancer-specific quality of life in ocular graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Yinglin Liao; Wenxin Zhao; Jing Yang; Shaowen Wu; Ling Jin; Fen Huang; Lingyi Liang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-27       Impact factor: 3.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.